| Comparison of both averages and variances |
| Assurance of switchability |
| Encouragement or reward of pharmaceutical companies to manufacture a better formulation |
| Control of type I error rate (consumer’s risk) at 5% |
| Allowance for determination of sample size |
| Admission of the possibility of sequence and period effects as well as missing values |
| User-friendly software application for statistical methods |
| Provision of easy interpretation for scientists and clinicians |
| Minimization of increased cost for conducting bioequivalence studies |
Source: [6].